Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Sydnexis, Inc.

Sydnexis Receives Complete Response Letter from FDA for SYD-101 to Slow Pediatric Myopia Progression
From Sydnexis, Inc.
Via Business Wire
Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
From Sydnexis, Inc.
Via Business Wire
Sydnexis Announces Three Abstracts Accepted for Poster Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
From Sydnexis, Inc.
Via Business Wire
Sydnexis Announces Positive CHMP Opinion in Europe for SYD-101 for Slowing the Progression of Pediatric Myopia
From Sydnexis, Inc.
Via Business Wire
Sydnexis Announces FDA Acceptance of New Drug Application for SYD-101 for the Treatment of Progression of Pediatric Myopia
From Sydnexis, Inc.
Via Business Wire
Perry J. Sternberg Joins Sydnexis as Chief Executive Officer
From Sydnexis, Inc.
Via Business Wire
Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures and Blue Stem Capital
From Sydnexis, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.